A Comprehensive Solution for E. coli Inclusion Bodies: From Ineffective Precipitation to an Industrial-Scale Process System for High-Activity Medicinal Proteins

In the field of industrial-scale expression of recombinant proteins in E. coli, inclusion body formation is a core, common challenge that limits product activity and hinders mass production. It is common during R&D for electrophoresis results to show excellent expression levels with bright bands, only for the protein to aggregate and become completely inactivated following purification. This ultimately results in hundreds of litres of fermentation broth being scrapped and weeks of R&D effort going to waste. A widespread misconception within the industry equates high expression levels with process success; in reality, inclusions are non-functional aggregates formed by misfolded proteins and constitute non-biologically active waste structures.

According to industry statistics, when E. coli is used to express complex eukaryotic proteins, proteins with multiple disulphide bonds, or highly hydrophobic functional proteins, over 80 per cent of the products exist in the form of inclusions. Most R&D teams rely solely on crude processes such as simple washing, urea-based rough solubilisation, and blind dialysis-based renaturation; ultimately, the renaturation rate falls below 10 per cent, rendering these methods entirely unsuitable for industrial-scale production and commercial profitability. This article systematically breaks down the standardised industrial-scale processing workflow for inclusion bodies, covering everything from analysing their causes, impurity removal and purification, denaturation and chain separation, gradient renaturation, to purification and quality enhancement.

Inclusion bodies are insoluble, dense protein particles formed by the misfolding and high aggregation of polypeptide chains within E. coli cells; they are not fermentation impurities,

1. Imbalance in folding rates: E. coli exhibits extremely high expression efficiency; the rate of protein synthesis driven by strong promoters far exceeds the rate at which intracellular chaperones can modify protein folding. Consequently, newly synthesised polypeptide chains are unable to adopt the correct three-dimensional conformation in a timely manner and rapidly aggregate via hydrophobic interactions, forming precursor structures of inclusions.

2. Deficiencies in the prokaryotic intracellular system: E. coli lacks eukaryotic modification organelles such as the endoplasmic reticulum and Golgi apparatus, and does not possess a comprehensive system for protein folding, glycosylation and disulphide bond modification; furthermore, the intracellular environment is highly reducing, which cannot support the formation of stable disulphide bonds, leading to widespread misfolding of medicinal and functional proteins containing multiple disulphide bonds.

3. Overload stress in fermentation processes: Conventional high-temperature induction at 37°C, stimulation with high concentrations of IPTG, and high-density fermentation conditions further exacerbate protein synthesis overload, significantly increasing the probability of erroneous peptide chain aggregation; these are key contributing factors to the high incidence of inclusions in industrial production.

In short, the faster the protein expression rate, the more complex the spatial structure, and the greater the number of disulphide bonds, the higher the probability of inclusion formation. However, the key point in industrial production is that inclusions are not entirely waste products. Compared with soluble impure proteins, inclusions offer the advantages of high purity, low levels of impurity proteins and resistance to degradation by intracellular enzymes. Through standardised artificial refolding processes, they can be refolded into structurally intact, functionally active soluble proteins that meet performance standards; this is the primary reason why inclusions are consistently recovered and processed in industrial production.

II. Core of Pre-treatment: Cell Lysis and Coarse Extraction of Inclusion Bodies with Impurity Removal

The core principle of inclusion body processing is ‘purification first, dissolution second’, thereby preventing the re-association of impurities; the presence of residual impurities is the primary cause of failure in subsequent re-association. Following cell lysis, the supernatant consists of soluble impure proteins, whilst the bottom precipitate comprises inclusion bodies, cell debris and nucleic acid impurities. The standardised industrial coarse extraction process is as follows:

1. Cell Resuspension and Protection: Cells are resuspended in a low-salt Tris buffer, with the addition of EDTA as an inhibitor to block proteolytic degradation pathways. The entire process is carried out at low temperatures to stabilise and protect the protein backbone, thereby preventing structural damage during the pre-treatment stage.

2. High-pressure homogenisation: The bacterial cells are thoroughly disrupted via a high-pressure homogenisation process to completely release intracellular inclusions, thereby eliminating issues of cell encapsulation and residual carry-over, and ensuring thorough purification in subsequent steps.

3. Low-temperature high-speed centrifugation for enrichment: Centrifugation is performed at 12,000–15,000 rpm at 4 °C; the supernatant containing soluble protein contaminants is discarded, and the dense white inclusion precipitate at the bottom is collected.

4. Detergent-based coarse washing to remove impurities: The precipitate is thoroughly resuspended and washed using a specialised washing buffer containing Triton X-100. The detergent’s properties are utilised to dissolve cell membrane fragments, lipid impurities and adsorbed impure proteins, thereby eliminating interfering factors at source. After repeating the washing process 2–3 times, the impurity removal rate can reach over 90 per cent, yielding a high-purity crude inclusion body precipitate, which lays the foundation for subsequent denaturation and renaturation.

III. Denaturation and Unfolding: Process for the Complete Dissolution of High-Purity Inclusion Bodies

The coarsely extracted inclusion bodies remain in a highly aggregated, insoluble state. High-concentration denaturants are required to break intermolecular hydrophobic bonds, hydrogen bonds and other intermolecular forces, thereby completely dismantling the erroneous spatial structure and converting the aggregated proteins into linear, single-chain peptides, thus creating the conditions for precise renaturation. The industrial sector predominantly employs two distinct denaturation systems, tailored to different protein characteristics:

1. 8M urea denaturation system (general-purpose, mass-production type): This system exerts a mild denaturing effect, causing minimal damage to the protein backbone. It offers controllable costs and is suited to large-scale industrial production. It is suitable for common recombinant proteins with conventional structures and low levels of aggregation, and is the preferred solution for industrial mass production.

2. 6 M guanidine hydrochloride denaturation system (high-efficacy purification type): This system offers greater denaturation penetration and chain-unravelling capacity, capable of thoroughly dissolving highly aggregated, extremely insoluble and stubborn inclusions; it is suitable for complex structural pharmaceutical proteins. The drawbacks are higher costs and a tendency to cause irreversible damage to some proteins under high-concentration conditions, necessitating strict control of process parameters.

Standard Operating Procedure: Slowly add the purified inclusion body precipitate to the corresponding denaturation buffer and gently stir at low temperature for 2–4 hours to dissolve it, thereby avoiding the issue of localised high concentrations. Once dissolution is complete, centrifuge at high speed to remove trace amounts of insoluble residue and collect the clear denatured protein solution. Rapid pouring and vigorous shaking must be strictly avoided throughout the process to prevent secondary protein aggregation and compromise the denaturation effect.

IV. Core Process: Controllable Gradient Renaturation—Determining Mass-Production Activity and Yield

Renaturation is the critical make-or-break stage of the inclusion complex process. Essentially, it involves the gradual, stepwise removal of denaturants to allow linear polypeptide chains to fold autonomously and in an ordered manner, thereby restoring their native spatial conformation and biological activity. Conventional laboratory methods, such as dialysis with pure water or rapid dilution, cause a sudden drop in denaturant concentration, leading to the rapid, disordered aggregation of polypeptide chains and the re-formation of precipitates; this is the primary cause of low renaturation rates. To address proteins of varying complexity, the industry has implemented three standardised renaturation protocols with high success rates:

1. Gradient dilution denaturation (entry-level, general-purpose): High-concentration denatured protein solution is added drop by drop at a constant rate to the denaturation buffer, achieving a gradual decrease in denaturant concentration. This method is simple to operate, suitable for large-scale production, and applicable to conventional functional proteins with simple structures and no disulphide bonds.

2. Stepwise dialysis denaturation (industry standard): A urea dialysis system with a concentration gradient of 6 M → 4 M → 2 M → 1 M → 0 M is established, with the dialysis buffer replaced every 8–12 hours to allow sufficient time for the polypeptide chains to fold correctly. Combined with a dedicated redox buffer system, this method enables precise control of disulphide bond pairing, significantly reducing the probability of mispairing. It is suitable for the vast majority of pharmaceutical-grade recombinant proteins and is currently the preferred process for mass production by pharmaceutical companies.

3. On-column in situ renaturation (high-end precision type): Denatured proteins are bound to ion-exchange or hydrophobic chromatography resins, with gradient elution and denaturant stripping carried out within the chromatography column; the solid-phase immobilisation prevents protein molecules from clumping together. This process ensures uniform renaturation, high product purity and stable yields. It is suitable for high-value, difficult-to-renature pharmaceutical proteins and is the standard process for drug registration.

Core adjuvants for enhanced denaturation: Denaturation buffers must be supplemented with stabilisers such as glycerol and sucrose to improve the folding stability of polypeptide chains; when combined with the GSH/GSSG redox pair, they precisely regulate the formation of disulphide bonds, addressing the issues of misfolding and loss of activity in polysulphide-containing proteins at their root cause, thereby significantly increasing the proportion of active protein.

V. Post-recovery purification: Removal of isomers to achieve pharmaceutical-grade purity standards

The completion of renaturation is not the end of the process; misfolded isomers, trace aggregates and protein fragments still remain within the renaturation system. These impurities must be removed through purification to ensure the activity, purity and batch consistency of the final product.

1. Pre-treatment for impurity removal: Following denaturation, a combination of low-temperature high-speed centrifugation and 0.22 μm precision filtration is employed to thoroughly remove secondary aggregates and macromolecular impurities;

2. Multi-stage chromatographic purification: A multi-stage coupled chromatography process involving ion exchange, hydrophobic chromatography and gel exclusion chromatography is used to precisely separate naturally active protein monomers, misfolded proteins and non-functional aggregates;

3. Ultrafiltration and buffer exchange for final formulation: An ultrafiltration concentration process is employed to transfer the product to the final buffer, thoroughly removing residual denaturants and process additives to complete the preparation of the final product.

Upon implementation of the entire purification process, the purity of the recombinant protein can reach over 95 per cent (pharmaceutical grade), with significantly improved activity recovery rates and product stability, fully meeting the requirements for industrial production and drug registration.

VI. Process Summary and Industrial Value

The core logic of the industrial-scale processing of E. coli inclusions can be summarised as follows: purification and decontamination → thorough denaturation → gradual, slow renaturation → purification and quality enhancement. In traditional R&D thinking, inclusions are often regarded as waste products resulting from failed experiments; however, within a standardised industrial system, inclusions—owing to their inherent advantages of high purity and low levels of contaminating proteins—become a high-quality raw material for the low-cost production of highly active recombinant proteins.

By precisely controlling the parameters throughout the entire process of denaturation, renaturation and purification, what were originally discarded, ineffective protein precipitates can be transformed into highly active recombinant proteins that meet pharmaceutical and industrial standards, thereby significantly reducing R&D and mass production costs. For synthetic biology companies and R&D personnel, mastering the entire inclusion body processing workflow is crucial for overcoming the bottlenecks in the mass production of complex recombinant proteins, improving product yield and achieving commercialisation; it also represents the key technological barrier distinguishing laboratory-scale R&D from industrial-scale production.